IVIG (Intravenous Immune Globulin) Infusion Guide for Ontario

Purpose
To provide health care practitioners involved in the infusion of IVIG with best practice information. This document can be incorporated into institution specific policies and procedures.

This guide does not apply to Subcutaneous Infusion of Immune Globulin.

General Principles
- Refer to institution specific policies
- Use the Adjusted Body Weight Dosing Calculator where appropriate for calculating dosage for adult patients. http://www.transfusionontario.org/dose
  - At least every 6 months
  - If significant weight change reported by patient
- Round dose to the nearest vial size (e.g. 2.5 or 5g to ensure adequate therapy and efficient use of product).
- Avoid infusing different brands at a single visit/infusion course. Maintain chronically infused patients on the same IVIG brand when possible.
- Use aseptic technique when handling IVIG.
- Pooling of product is generally not recommended due to risk of contamination and potential wastage. If required, pooling of the product should be performed in a laminar flow hood in the Transfusion Medicine Laboratory (TML) or Pharmacy.
  - Pooling is not required to prevent bubbling. Bubbling can be eliminated by bringing product to room temperature prior to infusion

Pre-Infusion
- Verify that there is an order and the clinical indication is documented.
- Verify that informed consent for transfusion has been obtained.
- Identify patients at increased risk for:
  - TACO (Transfusion Associated Circulatory Overload) – neonates, elderly, hypertension, cardiac or renal dysfunction
  - Hemolysis - blood group A, B or AB; more common with high dose treatment
  - Thromboembolic events – obesity, elderly, hypertension, history of vascular disease or thrombotic episodes or disorders, hyperviscosity syndrome, decreased mobility, severe dehydration, diabetes, presence of indwelling lines (central venous access devices)
  - Aseptic Meningitis - history of migraines
  - Anaphylaxis – patients known to have anti-IgA antibodies
- Review history of previous reactions to IVIG or other blood components.
- Assess patient’s clinical status on day of infusion and document relevant changes since previous infusion.
- Record known allergies, medications, and weight if indicated.
- Document baseline vital signs.
- Determine whether any pre-infusion blood work is required
  - blood group before first infusion
  - CBC at prescribed intervals
  - liver and renal function tests if indicated
  - platelet count for ITP patients
  - plasma IgG levels for immunodeficient patients at prescribed intervals
**Infusion**

**Preparing Infusion**

**Prime** line with normal saline or 5% dextrose (refer to package insert/monograph). Use standard vented IV tubing – no filter is required. Minimize bubbling by allowing product to come to room temperature and avoid shaking.

To ensure proper venting of IVIG bottle:
- Close roller clamp on IV set
- Place bottle on a flat surface and spike at a 90° angle through the center circle of the stopper
- Invert and hang bottle on IV pole
- Squeeze drip chamber to ½ full
- Open vent on drip chamber – this allows air to enter the bottle. IVIG will not flow if not properly vented
- **Important:** Close vent prior to spiking the next bottle, then hang bottle and open vent.

**Starting Infusion**

- **Set** initial infusion rate. An infusion pump is recommended to set precise infusion rates and detect air in the line when the IVIG bottle is empty thereby providing added safety.

  **Initial rate:** A slow infusion rate (e.g. 0.5 mL/kg/hr) is recommended for the first 30 minutes

  ▼

  **Check vital signs**

  ▼

  **Rate increases:** as per institutional policy and patient tolerance

  ▼

  **Repeat vital signs at required intervals.**
  (e.g. when increasing rate)

  ▼

  **Maximum rate:** as per institutional policy (e.g. 4mL/kg/hr)
  **CAUTION:** Manufacturer’s monographs may allow for faster rates. These high infusion rates only apply to patients who previously tolerated this IVIG brand and have no preexisting risk factors (see list in pre-infusion section) or history of adverse reactions.

- **Monitor** patient for signs of adverse reactions. If an adverse reaction is suspected STOP infusion, maintain IV access, record vital signs, notify patient’s physician, and report to TML or Pharmacy (refer to Adverse Reaction Chart).

**Post Infusion**

- **Complete** documentation including dose, lot numbers, and brand if known.
- **Report** and return to TML or Pharmacy any unused or defective vials including any vials associated with serious adverse reactions.
- **Educate** patients by providing them with a fact sheet including post-infusion adverse reactions instructions (refer to IVIG Facts for Outpatients).
**Adverse Reaction Chart for IVIG Infusion**

**STOP** infusion and notify patient’s physician if:
- Change in systolic or diastolic blood pressure of 20 percent or more.
- Temperature 38°C or more and increased by at least 1°C from baseline
- Appearance of flushing, rigors (shivering), urticaria, itching, wheezing, tightness in chest, abdominal cramps, headache, nausea/vomiting or red urine.

Report all suspected reactions to TML or Pharmacy.

<table>
<thead>
<tr>
<th>Signs and Symptoms</th>
<th>Severity</th>
<th>Frequency</th>
<th>Reaction Type</th>
<th>Actions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache (during or 1-3 days post-infusion)</td>
<td>Mild</td>
<td>Common</td>
<td>IVIG headache</td>
<td><strong>Stop IVIG. Consult Physician.</strong> The infusion may be restarted at a reduced rate. Recurrent reactions may require appropriate premedication and/or a change in IVIG product. Report to TML/Pharmacy.</td>
</tr>
<tr>
<td>Low grade fever, flushing, rigors, chills</td>
<td>Mild</td>
<td>Occasional</td>
<td>Febrile Non Hemolytic Reaction</td>
<td><strong>Stop IVIG. Consult Physician.</strong> Give medications as ordered. If symptoms are mild, infusion may be restarted at a reduced rate as per physician's order. Recurrent reactions require appropriate premedication and/or a change in IVIG product. Report to TML/Pharmacy.</td>
</tr>
<tr>
<td>Urticaria, rash, itchiness, flushing, abdominal pain, nausea, and vomiting</td>
<td>Mild</td>
<td>Occasional</td>
<td>Minor Allergic</td>
<td><strong>Stop IVIG. Consult Physician.</strong> Give medications as ordered. If symptoms are mild, infusion may be restarted as per physician's order. Recurrent reactions require appropriate premedication and/or a change in IVIG product. Report to TML/Pharmacy.</td>
</tr>
<tr>
<td>Dyspnea, itchiness, urticaria, facial and/or tongue swelling, chest tightness,</td>
<td>Moderate to Severe</td>
<td>Rare</td>
<td>Anaphylaxis/ Anaphylactoid</td>
<td><strong>Stop IVIG. Consult Physician.</strong> May require epinephrine promptly. Reaction can be caused by an allergen to which the patient has a significant allergy. Testing for anti-IgA antibodies should be done following an anaphylactic reaction. Report to TML/Pharmacy.</td>
</tr>
<tr>
<td>hypotension, tachycardia, nausea/ vomiting, and anxiety</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspnea, hypertension, orthopnea, cyanosis, cough tachycardia, increased jugular</td>
<td>Mild to Severe</td>
<td>Occasional</td>
<td>Transfusion Associated Circulatory Overload (TACO)</td>
<td><strong>Stop IVIG. Consult Physician.</strong> Give medications as ordered (e.g. diuretic), Slow infusion rate for subsequent infusions. Report to TML/Pharmacy.</td>
</tr>
<tr>
<td>venous pressure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever, back pain, dyspnea changes in urine colour (red/brown urine ), jaundice,</td>
<td>Mild to Severe</td>
<td>Occasional</td>
<td>Acute (less than 24hr) or Delayed (greater than 24hr) Hemolysis*</td>
<td><strong>Stop IVIG. Consult Physician.</strong> Do not restart. Usually due to anti-A or anti-B antibodies in IVIG directed against a patient whose blood group is A, B, or AB. Report to TML/Pharmacy.</td>
</tr>
<tr>
<td>extreme fatigue, feeling faint</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Hemolysis is defined as:
A drop in hemoglobin of at least 10g/L
a positive direct antiglobulin test (DAT)

**AND**
at least two of the following:
increased reticulocyte count
increased lactate dehydrogenase
low haptoglobin
hyperbilirubinemia
hemoglobinemia
hemoglobinuria

**Version 2.0 October 31, 2015**
### Adverse Reaction Chart for IVIG Infusion

| Severe and incapacitating headache with nuchal rigidity, drowsiness, fever, lethargy, photophobia, painful eye movements, nausea, vomiting, diarrhea, pharyngitis, deterioration of mental status | Severe | Rare | Aseptic Meningitis | Stop IVIG. Consult Physician. Do not restart. Usually resolves spontaneously in 1-2 days. Report to TML/Pharmacy. |
| Peripheral edema, periorbital edema, urination changes, increased serum creatinine, hypertension, back pain, flank pain, blood in urine | Severe | Rare | Acute Renal Failure | Stop IVIG. Consult Physician. Predisposing factors: age>65, diabetes mellitus, preexisting renal insufficiency. Report to TML/Pharmacy. |
| Symptoms related to myocardial infarction, transient ischemic attack, stroke, deep vein thrombosis | Severe | Rare | Thromboembolic events | Stop IVIG. Consult Physician. Possibly related to increased viscosity and patient comorbidities. Report to TML/Pharmacy. |
| Symptoms of new viral or prion infection (variable) and presenting weeks following infusion | Severe | Rare | Transfusion Transmitted Infections | Report any new infections suspected to be due to the blood product to TML/Pharmacy. |

### References-Sources of Information for the IVIG (Intravenous Immune Globulin)

**Infusion Guide for Ontario**

Members of Ontario IVIG Standard Infusion Guideline Working Group

- Ms. Brenda Reid, Clinical Nurse Specialist Immunology/Allergy, SickKids
- Ms. Yvonne Davis-Read, Transfusion Safety Nurse, St. Michael’s Hospital
- Ms. Laura Harrison, Transfusion Safety Officer, Trillium Health Partners
- Ms. Ana Lima, Transfusion Safety Nurse, Sunnybrook Health Centre
- Ms. Wilma Koopman, Nurse Practitioner, London Health Sciences Centre Neuromuscular Clinic

Past Contributors

- Ms. Liese Bolte, Charge Technologist, Transfusion Medicine, Royal Victoria Hospital
- Ms. Julie DiTomasso, Transfusion Safety Officer, Hamilton Health Sciences
- Ms. Jane Cartwright, Transfusion Safety Officer, Credit Valley Hospital
- Ms. Kathleen Eckert, Transfusion Safety Officer, London Laboratory Services
- Ms. Kathleen McShane, Transfusion Safety Officer, Hospital for Sick Children
- Ms. Doris Neurath, Manager Transfusion Medicine, The Ottawa Hospital
- Ms. Lina D’Onofrio, Transfusion Safety Officer, University Health Network
- Ms. Margaret Samide, Clinical Nurse Specialist, Grand River Regional Cancer Centre
- Ms. Irene Skinner, Charge Technologist Transfusion Medicine, Lakeridge Health Corporation
- Ms. Sylvie Malloy, CON(C) Hamilton Health Sciences